Mogroside V exerts anti-inflammatory effect via MAPK-NF-κB/AP-1 and AMPK-PI3K/Akt/mTOR pathways in ulcerative colitis

To evaluate the anti-inflammatory function of mogroside V (MGV) and its molecular mechanism, dextran sulfate sodium (DSS)-induced colitis and lipopolysaccharide (LPS)-induced inflammation model were used in the study. Results indicated that MGV (100 mg/kg/day) supplementation in diet improved the health status of mice. Western blot results showed that MGV inhibited the expression pro-inflammatory factors of colonic tissues. MGV significantly reduced the expressions of pro-inflammatory cytokines in the LPS-stimulated RAW264.7 cells, also inhibited the phosphorylation of MAPKs. MGV promoted the activation of AMPK and inhibition the PI3K/Akt/mTOR pathway. Compound C (AMPK inhibitor) and SC79 (Akt activator) reversed the alleviating effect of MGV on the expression pro-inflammatory factors via a hub molecule of mTOR, indicating that MGV inhibits LPS-stimulated inflammation by triggering the AMPK-PI3K/Akt/mTOR pathway. Collectively, MGV can potentially be used in the treatments of ulcerative colitis, and it exerts anti-inflammatory effect via MAPK-NF-κB/AP-1 and AMPK-PI3K/Akt/mTOR pathways in ulcerative colitis.